{"id":52161,"date":"2025-12-29T13:47:11","date_gmt":"2025-12-29T05:47:11","guid":{"rendered":"https:\/\/flcube.com\/?p=52161"},"modified":"2025-12-29T13:47:12","modified_gmt":"2025-12-29T05:47:12","slug":"hbm-holdings-and-lannacheng-biotech-forge-strategic-alliance-for-next-generation-rdcs-in-precision-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52161","title":{"rendered":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology"},"content":{"rendered":"\n

HBM Holdings Limited<\/strong> (HKG: 2142<\/a>) announced a long\u2011term strategic collaboration<\/strong> with Yantai Lannacheng Biotechnology Co., Ltd.<\/strong> to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs)<\/strong> for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform<\/strong> and Lannacheng\u2019s radiopharmaceutical expertise.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Companies<\/strong><\/td>HBM Holdings (Harbour BioMed), Yantai Lannacheng Biotechnology<\/td><\/tr>
Focus<\/strong><\/td>Radionuclide Drug Conjugates (RDCs) for solid tumors<\/td><\/tr>
Technology<\/strong><\/td>Fully human monoclonal antibodies (H2L2 & HCAb formats)<\/td><\/tr>
Collaboration Scope<\/strong><\/td>Co\u2011development, manufacturing, clinical translation<\/td><\/tr>
Strategic Value<\/strong><\/td>Addresses tumor heterogeneity & resistance via bystander effect<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

RDC Technology & Differentiation<\/h2>\n\n\n\n

Mechanism of Action<\/strong>: RDCs deliver radioactive payloads<\/strong> directly into tumor lesions via tumor\u2011antigen\u2011specific ligands, minimizing off\u2011target damage to healthy tissue.<\/p>\n\n\n\n

Advantages Over Traditional Modalities<\/strong>:<\/p>\n\n\n\n

Feature<\/th>RDCs<\/th>Traditional Radiotherapy<\/th>Antibody\u2011Drug Conjugates (ADCs)<\/th><\/tr><\/thead>
Precision<\/strong><\/td>Molecular targeting<\/td>Anatomical targeting<\/td>Molecular targeting<\/td><\/tr>
Bystander Effect<\/strong><\/td>\u2705 Kills adjacent antigen\u2011negative cells<\/td>\u274c Limited<\/td>\u26a0\ufe0f Dependent on payload<\/td><\/tr>
Tumor Heterogeneity<\/strong><\/td>\u2705 Overcomes resistance<\/td>\u274c Limited<\/td>\u26a0\ufe0f Vulnerable to antigen loss<\/td><\/tr>
Safety Profile<\/strong><\/td>Reduced systemic toxicity<\/td>High local toxicity<\/td>Manageable but payload\u2011dependent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The bystander effect<\/strong> enables RDCs to eradicate neighboring tumor cells and remodel the tumor microenvironment, offering a potential solution for cold tumors<\/strong> with low antigen expression.<\/p>\n\n\n\n

Harbour Mice\u00ae Platform & HCAb Format<\/h2>\n\n\n\n

Technology Overview<\/strong>:<\/p>\n\n\n\n

    \n
  • Fully Human Antibodies<\/strong>: Generated directly from transgenic mice; no humanization or complex engineering required<\/li>\n\n\n\n
  • Dual Formats<\/strong>: Classical H2L2<\/strong> and heavy\u2011chain\u2011only (HCAb)<\/strong> antibodies<\/li>\n\n\n\n
  • HCAb Advantages<\/strong>:<\/li>\n\n\n\n
  • Size<\/strong>: Half the molecular weight of conventional IgG \u2192 superior tissue penetration<\/strong><\/li>\n\n\n\n
  • Specificity<\/strong>: Enhanced tumor targeting with reduced off\u2011target binding<\/li>\n\n\n\n
  • Stability<\/strong>: High physicochemical stability ideal for conjugation chemistry<\/li>\n\n\n\n
  • Immunogenicity<\/strong>: Low risk of anti\u2011drug antibodies (ADAs)<\/li>\n<\/ul>\n\n\n\n

    RDC Development Synergy<\/strong>: The HCAb format\u2019s compact size and high tumor penetration optimize drug\u2011to\u2011antibody ratio (DAR)<\/strong> and biodistribution, potentially improving therapeutic index.<\/p>\n\n\n\n

    Market Opportunity & Pipeline Strategy<\/h2>\n\n\n\n

    Target Indications<\/strong>: The collaboration has mapped strategic development across six priority oncology areas<\/strong>:<\/p>\n\n\n\n

    Indication<\/th>China Incidence (Annual)<\/th>Current Standard of Care<\/th>RDC Value Proposition<\/th><\/tr><\/thead>
    Lung Cancer (NSCLC\/SCLC)<\/strong><\/td>820,000 cases<\/td>Chemo, IO, ADCs<\/td>Bystander effect for heterogenous tumors<\/td><\/tr>
    Prostate Cancer<\/strong><\/td>120,000 cases<\/td>Hormone therapy, radioligands<\/td>Enhanced precision & safety<\/td><\/tr>
    Gastric Cancer<\/strong><\/td>480,000 cases<\/td>Chemo, HER2\u2011targeted therapy<\/td>Novel antigen targets (Claudin18.2)<\/td><\/tr>
    Colorectal Cancer<\/strong><\/td>550,000 cases<\/td>Chemo, anti\u2011EGFR mAbs<\/td>Overcoming KRAS\u2011mutated resistance<\/td><\/tr>
    Pancreatic Cancer<\/strong><\/td>110,000 cases<\/td>Chemo (FOLFIRINOX)<\/td>Deep tumor penetration challenge<\/td><\/tr>
    Hepatocellular Carcinoma<\/strong><\/td>410,000 cases<\/td>TKIs, IO combos<\/td>AFP\u2011targeted RDC opportunity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Pipeline Timeline<\/strong>: IND filing for first candidate (HBM\u2011RDC\u201101)<\/strong> targeting PSMA\u2011positive prostate cancer<\/strong> expected Q3\u202f2026<\/strong>; Phase\u202fI trial initiation Q1\u202f2027<\/strong>.<\/p>\n\n\n\n

    Commercial & Financial Outlook<\/h2>\n\n\n\n

    China\u2019s radiopharmaceutical market<\/strong> is projected to reach \u00a528\u202fbillion<\/strong> (\u2248\u202fUS$3.9\u202fbillion) by 2030, growing at a 25% CAGR, driven by nuclear medicine infrastructure expansion.<\/p>\n\n\n\n

    Metric<\/th>2027E<\/th>2030E<\/th><\/tr><\/thead>
    China RDC addressable patient pool<\/strong><\/td>1.2\u202fmillion<\/td>1.8\u202fmillion<\/td><\/tr>
    Peak HBM\u2011Lannacheng penetration<\/strong><\/td>3%<\/td>8%<\/td><\/tr>
    Estimated annual RDC therapy cost<\/strong><\/td>\u00a5180,000<\/td>\u00a5150,000 (post\u2011NRDL)<\/td><\/tr>
    Potential peak revenue<\/strong><\/td>\u00a5648\u202fmillion<\/td>\u00a52.16\u202fbillion (US$90\u2011300\u202fmillion)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Deal Structure<\/strong>: Undisclosed equity exchange; typical biotech partnerships involve milestone payments<\/strong> of \u00a5100\u2011200\u202fmillion plus tiered royalties<\/strong> (8\u201112% of net sales).<\/p>\n\n\n\n

    Competitive Landscape<\/h2>\n\n\n\n
    Player<\/th>Platform<\/th>Stage<\/th>Differentiation<\/th><\/tr><\/thead>
    HBM\/Lannacheng<\/strong><\/td>HCAb\u2011based RDCs<\/td>Pre\u2011clinical<\/td>Fully human, superior tissue penetration<\/td><\/tr>
    Novartis (Pluvicto)<\/strong><\/td>PSMA\u2011targeted RDC<\/td>Approved (US\/EU)<\/td>First\u2011to\u2011market but humanized antibody<\/td><\/tr>
    BMS (RYZ101)<\/strong><\/td>SSTR2\u2011targeted RDC<\/td>Phase\u202fIII<\/td>Targeting neuroendocrine tumors<\/td><\/tr>
    ITM (ITM\u201111)<\/strong><\/td>FAP\u2011targeted RDC<\/td>Phase\u202fII<\/td>Broad solid tumor applicability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    The partnership positions HBM as the first domestic player<\/strong> with a next\u2011generation RDC platform<\/strong>, potentially leapfrogging multinational competitors in China.<\/p>\n\n\n\n

    Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n

    This brief contains forward\u2011looking projections regarding pipeline timelines, market size, revenue potential, and competitive positioning for the HBM\u2011Lannacheng RDC collaboration. Actual results may differ based on clinical trial outcomes, NMPA regulatory decisions, and competitive dynamics in the radiopharmaceutical sector.<\/p>\n","protected":false},"excerpt":{"rendered":"

    HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co.,…<\/p>\n","protected":false},"author":1,"featured_media":52162,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,129,916,3692],"class_list":["post-52161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-hbm-holdings","tag-hkg-2142","tag-lannacheng-biotechnology"],"yoast_head":"\nHBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52161\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology\" \/>\n<meta property=\"og:description\" content=\"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52161\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T05:47:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-29T05:47:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology\",\"datePublished\":\"2025-12-29T05:47:11+00:00\",\"dateModified\":\"2025-12-29T05:47:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161\"},\"wordCount\":610,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2902.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"HBM Holdings\",\"HKG: 2142\",\"Lannacheng Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52161#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52161\",\"name\":\"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2902.webp\",\"datePublished\":\"2025-12-29T05:47:11+00:00\",\"dateModified\":\"2025-12-29T05:47:12+00:00\",\"description\":\"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52161\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2902.webp\",\"width\":1080,\"height\":608,\"caption\":\"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52161#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology - Insight, China's Pharmaceutical Industry","description":"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52161","og_locale":"en_US","og_type":"article","og_title":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology","og_description":"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.","og_url":"https:\/\/flcube.com\/?p=52161","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T05:47:11+00:00","article_modified_time":"2025-12-29T05:47:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52161#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52161"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology","datePublished":"2025-12-29T05:47:11+00:00","dateModified":"2025-12-29T05:47:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52161"},"wordCount":610,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52161#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","keywords":["ADC \/ XDC","HBM Holdings","HKG: 2142","Lannacheng Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52161#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52161","url":"https:\/\/flcube.com\/?p=52161","name":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52161#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52161#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","datePublished":"2025-12-29T05:47:11+00:00","dateModified":"2025-12-29T05:47:12+00:00","description":"HBM Holdings Limited (HKG: 2142) announced a long\u2011term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next\u2011generation Radionuclide Drug Conjugates (RDCs) for cancer therapy, leveraging HBM\u2019s proprietary Harbour Mice\u00ae platform and Lannacheng\u2019s radiopharmaceutical expertise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52161#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52161"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52161#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","width":1080,"height":608,"caption":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52161#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next\u2011Generation RDCs in Precision Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52161"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52161\/revisions"}],"predecessor-version":[{"id":52163,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52161\/revisions\/52163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52162"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}